SynthesisEuropean heart journal2012
Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy.
Synthesis in European heart journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis.Journal of global health · 2024Pooled it
- Does infection with human immunodeficiency virus have any impact on the cardiovascular outcomes following percutaneous coronary intervention?: a systematic review and meta-analysis.BMC cardiovascular disorders · 2017Pooled it
- The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis.BioMed research international · 2014Pooled it
- De novo electrocardiographic abnormalities in persons living with HIV.Scientific reports · 2021Trial
- Targeting thrombogenicity and inflammation in chronic HIV infection.Science advances · 2019Trial
- Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Annals of internal medicine · 2014Trial
- Trial
- Review
- Implementing screening for hypertension in archetypal HIV primary care: a mixed-methods assessment.BMC health services research · 2022Article
- AIDS at 40Global health & medicine · 2022Review
- Assessment of Clinical Features in HIV-Infected Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention in China.Journal of interventional cardiology · 2022Article
- Coronary artery disease in patients with human immunodeficiency virus infection.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Review
- HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome.Journal of the American Heart Association · 2020Observational
- Coronary Microvascular Dysfunction in HIV: A Review.Journal of the American Heart Association · 2020Review
- Elevated indoleamine-2,3-dioxygenase enzyme activity in a novel mouse model of HIV-associated atherosclerosis.AIDS (London, England) · 2019Article
- Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).BMC medicine · 2019Article
- Coronary Artery Disease Manifestations in HIV: What, How, and Why.The Canadian journal of cardiology · 2019Review
- Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions.British journal of clinical pharmacology · 2018Article
- Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Cardiovascular Disease in the Setting of Human Immunodeficiency Virus Infection.Current cardiology reviews · 2018Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHighly active antiretroviral therapy (HAART) dramatically reduces human immunodeficiency virus (HIV)-associated morbidity and mortality, but adverse effects of HAART are becoming an increasing challenge, especially in the setting of acute coronary syndromes (ACS). We thus performed a comprehensive review of studies focusing on ACS in HIV patients. METHODS AND
resultsMEDLINE/PubMed was systematically screened for studies reporting on ACS in HIV patients. Baseline, treatment, and outcome data were appraised and pooled with random-effect methods computing summary estimates [95% confidence intervals (CIs)]. A total of 11 studies including 2442 patients were identified, with a notably low prevalence of diabetes [10.86 (4.11, 17.60); 95% CI]. Rates of in-hospital death were 8.00% (2.8, 12.5; 95% CI), ascribable to cardiovascular events for 7.90% (2.43, 13.37; 95% CI), with 2.31% (0.60, 4.01; 95% CI) developing cardiogenic shock. At a median follow-up of 25.50 months (11.25, 42; 95% CI), no deaths were recorded, with an incidence of 9.42% of acute myocardial infarction (2.68, 16.17; 95% CI) and of 20.18% (9.84, 30.51; 95% CI) of percutaneous coronary revascularization. Moreover, pooled analysis of the studies reporting incidence of acute myocardial infarction in patients exposed to protease inhibitors showed an overall significant risk of 2.68 (odds ratio 1.89, 3.89; 95% CI).
conclusionHuman immunodeficiency virus patients admitted for ACS face a substantial short-term risk of death and a significant long-term risk of coronary revascularization and myocardial infarction, especially if receiving protease inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.